September 12, 2017

Deinove has received funding from Bpifrance to work on the discovery of the next generation of antibiotics to fight antibiotic-resistant pathogens.

The Investments for the Future Program, operated by the French public investment bank Bpifrance, has granted €14.6M to the Antibiotics against Resistant Infectious Germs (AGIR) project, carried out by the Deinove group in collaboration with the Charles Violette Institute (CVI). The funds will be made available in the form of grants and loans spread over the five-year duration of the program, with €10.4M directed to Deinove and €4.2M for the CVI.